State Street Corp Increases Position in Context Therapeutics Inc. (NASDAQ:CNTX)

State Street Corp lifted its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 21.5% during the third quarter, Holdings Channel reports. The institutional investor owned 111,907 shares of the company’s stock after purchasing an additional 19,800 shares during the period. State Street Corp’s holdings in Context Therapeutics were worth $219,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CNTX. Renaissance Technologies LLC boosted its stake in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares during the period. Affinity Asset Advisors LLC raised its stake in Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,290,323 shares during the period. Ally Bridge Group NY LLC lifted its holdings in Context Therapeutics by 159.8% in the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares in the last quarter. Nantahala Capital Management LLC bought a new position in Context Therapeutics in the 2nd quarter worth approximately $3,881,000. Finally, Driehaus Capital Management LLC purchased a new stake in Context Therapeutics during the 2nd quarter valued at approximately $4,527,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Up 5.0 %

Context Therapeutics stock opened at $1.25 on Friday. Context Therapeutics Inc. has a 52-week low of $0.89 and a 52-week high of $2.75. The firm’s fifty day moving average is $1.58 and its 200 day moving average is $1.96. The company has a market cap of $93.75 million, a price-to-earnings ratio of -1.37 and a beta of 2.00.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, equities research analysts anticipate that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. D. Boral Capital assumed coverage on shares of Context Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $9.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Context Therapeutics presently has a consensus rating of “Buy” and an average price target of $6.80.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.